



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

The Secretary
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

October 19, 2018

Statement of Investor Complaints/Grievances pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for the Quarter ended September 30, 2018

Dear Sirs,

Pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, please find enclosed statement of investor complaints/grievances for the quarter ended September 30, 2018.

Thanking you.

Yours sincerely,

For Novartis India Limited

A handwritten signature in blue ink, appearing to read 'Trivikram Guda', written over a circular stamp.

Trivikram Guda
Company Secretary &
Compliance Officer

Encl.: as above



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

Name of the Company: Novartis India Limited

Scrip Code: 500672

Statement of Investor Complaints/Grievances pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for the Quarter ended September 30, 2018

Particulars	Number of Complaints
Complaints pending as on 01.07.2018	Nil
Complaints received during 01.07.2018 to 30.09.2018	2
Complaints resolved during 01.07.2018 to 30.09.2018	1
Complaints pending as on 30.09.2018	1

For Novartis India Limited

Trivikram Guda
Company Secretary &
Compliance Officer